Breaking News
urgent investor notice lead plaintiff deadline approaches for ventyx biosciences shareholders 2508

Latest Trends

Urgent Investor Notice: Lead Plaintiff Deadline Approaches for Ventyx Biosciences Shareholders


Michael Chen

April 7, 2024 - 12:45 pm


Legal Alert: Rosen Law Firm Announces Lead Plaintiff Deadline for Ventyx Biosciences Investors

NEW YORK, April 7, 2024 /PRNewswire/ -- Investors who recently acquired common stock in Ventyx Biosciences, Inc. during specific periods are being summoned to take note of the impending April 30, 2024 lead plaintiff deadline. Rosen Law Firm, renowned globally for its dedication to protecting investor rights, is issuing a reminder especially to those who purchased the company's stock either (i) pursuant or traceable to the documents issued for Ventyx's initial public offering (IPO) on October 21, 2021, or (ii) within the timeframe from October 21, 2021, to November 6, 2023.

Opportunity for Reimbursement: What Ventyx Investors Need to Know

Investors who acquired Ventyx Biosciences securities during the aforementioned periods may have a rightful claim to reparation without the need to bear any out-of-pocket fees or costs, courtesy of a contingency fee arrangement.

How to Participate in the Class Action

To become a member of the Ventyx class action, interested parties should proceed to Rosen Legal's case submission form or consider contacting Phillip Kim, Esq. via toll-free call at 866-767-3653 or via email at [email protected] for further information about the lawsuit process. It should be noted that a lawsuit has already been filed, and those wishing to serve as the lead plaintiff need to petition the Court no later than April 30, 2024.

Selecting Competent Counsel

The choice of legal representation in such matters is paramount. Rosen Law Firm emphasizes the importance of choosing qualified counsel with a solid history of successes in leading roles within similar litigation. The firm cautions that some firms issuing notices may lack comparable experience or the resources of other firms and might not be involved directly in litigating these cases but could rather be intermediaries that refer out cases. Rosen Law Firm stands apart by representing its global client base with a focus on securities class action lawsuits and shareholder derivative litigation, and it has a storied record of obtaining favorable outcomes for investors.

Rosen Law Firm's Litigation Successes

To illustrate its proficiency, Rosen Law Firm has secured what stands as the largest ever securities class action settlement against a Chinese company. Ranking Number 1 by ISS Securities Class Action Services based on the number of securities class action settlements in 2017, the firm has consistently been recognized within the top 4 since 2013. Its tireless efforts have resulted in the recovery of hundreds of millions of dollars for its clients. Notably, in 2019 alone, Rosen Law Firm successfully recouped over $438 million in investor funds. Lawrence Rosen, the founding partner, received the accolade of a 'Titan of Plaintiffs' Bar' by law360 in 2020, and many of the firm's attorneys have similarly garnered esteem by Lawdragon and Super Lawyers.

Significant Allegations in The Lawsuit

The allegations in the lawsuit call into question the veracity of the statements and disclosures made by Ventyx. According to the complaint, there were misleading statements or omissions that: (1) diminished the therapeutic effectiveness of Ventyx's leading product candidate, VTX958, for conditions such as psoriasis, psoriatic arthritis, and Crohn's disease; (2) therefore, the company's portrayal of VTX958's clinical and commercial potential was exaggerated; (3) consequently, Ventyx's abilities to create and market viable product candidates were misrepresented; (4) Ventyx's business prospects post-IPO were overvalued; and (5) due to this, the company's public statements were materially false and misleading at relevant times. With the true information now available to the public, the plaintiffs argue that there were subsequent losses endured by the investors.

For those who have invested in Ventyx and are considering joining the lawsuit, it's essential to take action. Head to the class action participation link or reach out to Phillip Kim, Esq. at Rosen Law Firm for more detailed information.

Know Your Rights as an Investor

It's crucially important for potential class members to understand that until a class is officially certified, you are not represented by counsel unless you personally hire one. The decision to acquire legal counsel is at the discretion of each investor, but you may also choose to remain an absentee class member and withhold action at this juncture. Moreover, the possibility of sharing in any prospective future recovery does not hinge on an individual's status as a lead plaintiff.

Stay Informed and Connected

Investors and interested parties are encouraged to stay updated on the case by following Rosen Law Firm's dedicated LinkedIn page at, on their Twitter feed at, or by liking their Facebook page at

Contacting Rosen Law Firm

For further details or inquiries, contact details are as follows:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]

Rosen Law Firm is accessible for those who require more information or wish to discuss their options in the wake of the Ventyx lawsuit.

Summary: A Call for Action

This public announcement is targeted at investors who have experienced financial loss due to the alleged misrepresentations of Ventyx Biosciences, Inc. The lead plaintiff deadline necessitates urgent attention, and Rosen Law Firm urges affected parties to consider their legal options. In selecting legal counsel, one should acknowledge the firm's successful track record, which signifies its capacity to thoroughly handle securities class actions and negotiate favorable settlements.

Note: This press release constitutes attorney advertising. Prior results do not guarantee similar outcomes in future cases.

End of the News Article